Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration AgreementsGlobeNewsWire • 05/04/21
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/23/21
Plus Therapeutics Reports First Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 04/22/21
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021GlobeNewsWire • 04/08/21
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing OrganizationGlobeNewsWire • 03/23/21
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/23/21
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business HighlightsGlobeNewsWire • 02/22/21
Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021GlobeNewsWire • 02/11/21
Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma TrialGlobeNewsWire • 12/15/20
Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer CenterGlobeNewsWire • 12/01/20
Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent GlioblastomaGlobeNewsWire • 11/19/20
Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial UpdateGlobeNewsWire • 11/13/20
Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma TrialGlobeNewsWire • 10/29/20
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/23/20
Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business HighlightsGlobeNewsWire • 10/22/20
Plus Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on October 22, 2020GlobeNewsWire • 10/14/20